Oxidative stress is enhanced in correlation with renal dysfunction: Examination with the redox state of albumin  by Terawaki, Hiroyuki et al.
Kidney International, Vol. 66 (2004), pp. 1988–1993
CLINICAL NEPHROLOGY – EPIDEMIOLOGY – CLINICAL TRIALS
Oxidative stress is enhanced in correlation with renal
dysfunction: Examination with the redox state of albumin
HIROYUKI TERAWAKI, KAZUNOBU YOSHIMURA, TOSHIO HASEGAWA, YUKIE MATSUYAMA,
TSUNEO NEGAWA, KENICHI YAMADA, MASATO MATSUSHIMA, MASAAKI NAKAYAMA,
TATSUO HOSOYA, and SEIICHI ERA
Department of Nephrology and Hypertension, Tokyo Jikei University School of Medicine, Tokyo, Japan; Division of Clinical
Research and Development, Tokyo, Japan; Department of Physiology, School of Medicine, Gifu University, Gifu, Japan; and
Department of Internal Medicine, Chiba-Higashi National Hospital, Chiba, Japan
Oxidative stress is enhanced in correlation with renal dysfunc-
tion: Examination with the redox state of albumin.
Background. Cardiovascular disease is known to be the most
important complication among patients with renal failure, and
oxidative stress has been proposed to play a major role as the
source of such complications. Human serum albumin (HSA)
is composed of human mercaptoalbumin (HMA) with cysteine
residues having reducing powers, of reversibly oxidized human
non-mercaptoalbumin-1 (HNA-1), and strongly oxidized hu-
man non-mercaptoalbumin-2 (HNA-2).
Methods. We used the “redox state of HSA” as a marker to
investigate the current status of oxidative stress in predialysis
patients with renal failure. The subjects were 55 nondialysis pa-
tients (31 males and 24 females) with chronic renal diseases,
and having various degrees of renal function. The subjects’ re-
dox state of HSA was determined by a high-performance liquid
chromatographic (HPLC) procedure, and the results presented
in terms of the ratios between HNA-total(HNA-1 + HNA-2)
and HNA-2.
Results. The values for each fraction of HNA-total (f(HNA-
total)) and f(HNA-2) were increased with a decrease of renal
functions, and a significant positive correlation with serum cre-
atinine (R = 0.529, P < 0.0001 and R = 0.618, P < 0.0001) was
detected. Multiple (forward stepwise) regression analysis using
f(HNA-total) and f(HNA-2) as the criterion variables was per-
formed, and creatinine was adopted as significant explanatory
variable in both equations.
Conclusion. We found that even before dialysis, oxidative
stress was enhanced in correlation with the level of renal dys-
function among patients with chronic renal failure. In the future,
antioxidant strategies should become part of treatment for pre-
dialysis renal failure.
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Cardiovascular disease (CVD) is the most important
complication for patients with end-stage renal disease
(ESRD). The mortality rate associated with CVD is ex-
tremely high, accounting for approximately 9% per year
(approximately 45% of total death) among ESRD pa-
tients that undergo dialysis, and it is the primary cause
of mortality. What characterizes the death of ESRD pa-
tients is the fact that mortality rate hardly seems to be
reflected by age [1], unlike patients without renal failure.
While risks associated with CVD among ESRD pa-
tients who reach dialysis are widely acknowledged, those
involving patients with renal failure before dialysis are
in the process of being properly identified, although not
well established yet. When compared with subjects with
normal renal function, the frequency of CVD has been
reported to be higher not only among dialysis patients
but also among predialysis patients with renal failure [2],
suggesting that factors promoting complications of the
cardiovascular system may already exist in predialysis pa-
tients with renal failure.
Oxidative stress has recently been proposed to play
a major role in the development of CVD among renal
failure patients [3]. In the past, backgrounds similar to
those of patients without renal failure, such as high blood
pressure and atherosclerosis, have been postulated, but
several reports have made it difficult to conceive these
as major causes [2]. To date, increases in blood con-
centrations of reactants resulting from oxidative stress
have mainly been reported among dialysis patients [4–7].
Further, other studies have reported that while admin-
istration of antioxidant substances, such as vitamin E
and acetylcysteine, reduce cardiovascular system events
among dialysis patients [8, 9], vitamin E did not exhibit
apparent effects among patients without renal failure
[10]. From these findings, that oxidative stress is, at least
in part, involved in CVD among chronic renal failure pa-
tients, seems virtually unquestionable.
1988
Terawaki et al: Renal function and redox state of albumin 1989
The aim of this study was to clarify whether oxida-
tive stress is already increased in predialysis chronic
renal failure patients. We adopted “the redox state
of human serum albumin (HSA)” as the marker of
oxidative stress. HSA is a protein composed of 585
amino acids. The amino residue at position 34 from the
N-terminus is a cysteine having a mercapto group
(SH group). The mercapto group deoxidizes other sub-
stances according to the degree of surrounding oxida-
tive stress, and is, itself, oxidized. From the view point
of cysteine residue, HSA is a mixture of human mer-
captoalbumin (HMA) in which the mercapto group is
not oxidized, human non-mercaptoalbumin-1, which is
the disulfide bond formation reversibly oxidized by ei-
ther cysteine or glutathione (HNA-1) [11], and human
non-mercaptoalbumin-2, which is strongly oxidized and
becomes sulfenic (−SOH), sulfinic (−SO2H), or sulfonic
(−SO3H) [12].
We, thus, performed measurements of the redox state
of HSA concurrently with various blood and urine tests
in 64 nondialysis patients with chronic renal disease hav-
ing different levels of renal function. As a result, our
study revealed a tight correlation between the oxidation-
reduction state of HSA and renal function, and confirmed
that oxidative stress was already increased in predialy-
sis chronic renal failure patients even before reaching
dialysis.
METHODS
The study involved 55 patients; 31 males and 24 females
aged between 40 and 70 (58 ± 14) years with chronic
renal disease (whose estimated creatinine clearance was
lower than 80 mL/min) who attended the Sakura National
Hospital for at least 6 months. Patients’ characteristics are
shown in Table 1. Regardless of the primary renal disease,
a total of 15 patients presented with diabetes mellitus.
Physical measurements including height, weight, and
blood pressure were taken, and then blood samples were
collected to measure the redox state of HSA; 2 mL was
drawn from the serum obtained by centrifugation, and
stored at −80◦C for 2 to 4 weeks until analysis. In ad-
dition, the following hematologic and biochemical tests
were performed: total protein, albumin, ALT, urea nitro-
gen, creatinine, uric acid, sodium, chlorine, potassium,
total calcium, inorganic phosphorus, total iron, total
cholesterol, HDL cholesterol, C-reactive protein, and
hemoglobin. Estimated endogenous creatinine clearance
(CCr) was calculated by the Cockcroft-Gault formula
[13].
We also instructed each patient to institute a 24-hour
urine collection, and used the concentration of sodium
and urea nitrogen from this to calculate the amount of
sodium excretion and the protein intake.
Table 1. Patient characteristics
Age years 58 ± 14
Male: Female 31: 24
Primary disease
CGN
IgA nephropathy 16
FSGS 4
MN 1
HSPN 1
FGO 1
MPGN 1
Crescentic GN 1
Not biopsy-proven 14
Nephrosclerosis 9
Diabetes nephropathy 3
Hereditary nephritis 1
Lupus nephritis 1
Polycystic kidney 1
Donor of RTx 1
Prescription
Calcium antagonist 26
ACEI 24
ARB 27
Loop diuretics 12
Thiazide diuretics 6
Allopurinol 8
Eicosapentaenoic acid 16
HMG-CoA RI 8
Probucol 2
Alpha-tocopherol 1
Predonisolone 6
Abbreviations are: CGN, chronic glomerulonephritis; FSGS, focal segmental
glomerulosclerosis; MN, membranous nephropathy; HSPN, Henoch-Schoenlein
purpura nephritis; FGO; focal glomerular obliterans; MPGN, membranopro-
liferative glomerulonephritis; crescentic GN, crescentic glomerulonephritis;
RTx, renal transplantation, ACEI; angiotensin-converting enzyme inhibitor;
ARB, angiotensin II receptor blocker; HMG-CoA RI, HMG-CoA reductase
inhibitor.
Measurement of the redox status of HSA was per-
formed by the method previously reported by Hayashi
et al [14], a high-performance liquid chromatographic
(HPLC) method. The chromatograph was equipped
with a fluorescence detection system that consisted of
a model AS-8010 autosampler, model CCPM double-
plunger pump, and model FS-8000 fluorescence detector
in conjunction with a model SC-8020 system controller
(all from Tosoh Co., Tokyo, Japan). A Shodex-Asahipak
ES-502 column (10- × 0.76-cm inner diameter, DEAE
form for ion-exchange HPLC; Showa Denko Co., Tokyo
Japan; column temperature, 35◦ ± 0.5◦) was used in this
study. Elution was performed by linear gradient elusion
with increasing ethanol concentrations from 0% to 5%
for serum in 0.05 mol/L sodium acetate and 0.40 mol/L
sodium sulfate mixture (pH 4.85) at a flow rate of 1.0 mL/
min. Deaeration of the buffer solution was performed by
bubbling helium.
From HPLC profiles of HSA obtained from these pro-
cedures, the value for each fraction of HMA, HNA-1,
and HNA-2 to total HSA (f(HMA), f(HNA-1), f(HNA-
2)) were calculated. Hematologic and biochemical tests
were measured with standard laboratory techniques.
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Table 2. The results of clinical data
Mean ± SD Range
Height cm 160.8 ± 7.6 145.0–175.0
Weight kg 58.7 ± 9.1 41.0–80.0
Body mass index 22.6 ± 2.5 18.3–29.4
Systolic blood pressure mm Hg 129.9 ± 17.0 90–175
Diastolic blood pressure mm Hg 78.7 ± 10.9 55–109
f (HMA) % 69.44 ± 7.26 47.64–83.02
f (HNA-1) % 28.59 ± 6.93 15.34–48.69
f (HNA-2) % 1.98 ± 0.69 1.13–4.11
f (HNA-total) % 30.57 ± 7.27 16.98–52.36
Total protein g/dL 7.0 ± 0.6 5.6–8.1
Albumin g/dL 4.1 ± 0.4 2.6–4.6
Alanine aminotransferase IU 16 ± 8 5–52
Urea nitrogen mg/dL 31 ± 17 12–84
Creatinine mg/dL 2.33 ± 2.35 0.75–12.62
Uric acid mg/dL 7.7 ± 2.0 3.9–11.5
Sodium mmol/L 139 ± 2 132–144
Chloride mmol/L 104 ± 3 98–110
Potassium mmol/L 4.6 ± 0.5 3.8–5.8
Total calcium mg/dL 9.4 ± 0.6 6.7–10.4
Inorganic phosphate mg/dL 3.8 ± 0.8 2.5–7.0
Total iron lg/dL 89 ± 26 26–168
Total cholesterol mg/dL 209 ± 36 155–304
HDL cholesterol mg/dL 57.5 ± 15.7 30.1–104.5
C-reactive protein mg/dL 0.1 ± 0.3 0.0–1.8
Hemoglobin g/dL 12.2 ± 1.8 8.8–15.9
Creatinine clearance mL/min 39.9 ± 18.5 4.1–73.9
Salt excretion g/day 8.61 ± 2.93 3.08–18.69
Estimated protein intake g/kgBW/day 0.68 ± 0.26 0.20–1.35
Statistical analysis
Values were expressed as mean ± standard deviation
unless otherwise stated.
We used the statistical software Stat View 5.0 (SAS
Institute, Inc., Cary, NC, USA). For the magnitude of
the correlation, we used Pearson’s correlation coefficient
(R). Item-category data (gender, primary disease, pre-
scription) were introduced into the analysis as dummy
variables. The correlation was determined to be signifi-
cant when P value was less than 0.05 (5%) with Fisher’s
Z transformation.
RESULTS
Table 2 shows the results of clinical data. Serum cre-
atinine in patients was a minimum of 0.75 mg/dL and
a maximum of 12.62 mg/dL. CCr was between 4.1 and
73.9 mL/min. The redox states of HSA, f(HMA), f(HNA-
1), and f(HNA-2) were between 47.64% and 83.02%,
15.34% and 48.69%, and 1.13% and 4.11%, respec-
tively. The fraction of total HNA (f(HNA-total), the sum
of f(HNA-1) of f(HNA-2)) was between 16.98% and
52.36%.
Relationships between the oxidized HSA (HNA-
total and HNA-2) and serum creatinine are shown in
Figure 1. A significantly positive correlation between cre-
atinine and both f(HNA-total) and f(HNA-2) was found
(R = 0.529, P < 0.0001 and R = 0.618, P < 0.0001).
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Fig. 1. The relationship between serum creatinine and f(HNA-total)
(A) and f(HNA-2) (B). Each value, f(HNA-total) and f(HNA-2), shows
a statistically significant positive correlation with serum creatinine.
CCr was also showed significant relationship with the re-
dox state of HSA (Fig. 2). Namely, CCr was correlated
negatively with f(HNA-total) and f(HNA-2) (R =
−0.525, P < 0.0001 and R = −0.539, P < 0.0001).
These findings indicate that decreased renal function con-
tributes to the oxidation of HSA.
Table 3 shows the results of correlation analyses
between the redox state of HSA and characteristics,
whereas Table 4 shows the results of correlation analy-
ses between the redox state of HSA and clinical data.
The items which showed statistically positive correlation
with either f(HNA-total) or f(HNA-2) were adopted as
the explanatory variables of multiple regression analysis.
Multiple (forward stepwise) regression analysis was
performed, in which the above adopted items were deter-
mined to be the explanatory variables, whereas f(HNA-
total) and f(HNA-2) were the criterion variables. Results
are shown in Table 5. Multiple regression equations us-
ing f(HNA-total) and f(HNA-2) as the criterion variables
were all formulated as significant equations. In the former
equation, creatinine and uric acid were adopted as signif-
icant explanatory variables, whereas creatinine, magne-
sium, and age were adopted in the latter. Namely, only
creatinine was adopted as significant explanatory vari-
ables in both equations.
DISCUSSION
Several pieces of collateral evidence have pointed to
the possibility of oxidative stress being promoted among
patients with chronic renal failure. However, if we look
at the status of oxidative stress in terms of an entire or-
ganism, the situation is much like the traditional Indian
parable of “The blind men and the elephant” because no
appropriate markers exist that could globally evaluate
the entire organism [3].
In this article, we evaluated the current status of ox-
idative stress in predialysis renal failure patients, with
the “redox state of serum albumin” as our marker. In
healthy adult males, HMA commonly makes up 75% of
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Fig. 2. The relationship between creatinine
clearance and f(HNA-total) (A) and f(HNA-
2) (B). Each value, f(HNA-total) and f(HNA-
2), shows a statistically significant negative
correlation with creatinine clearance.
Table 3. The correlation between f(HNA-total), f(HNA-2), and
patient characteristics
f (HNA-total) f (HNA-2)
R P value R P value
Age −.001 .9920 .084 .5439
Gender −.054 .6934 −.077 .5743
DM or NDM .219 .1080 .091 .5107
Prescription
Calcium antagonist .051 .7136 .246 .0706
ACEI −.073 .5976 .023 .8700
ARB −.103 .4532 −.030 .8256
Loop diuretics .400a .0025 .241 .0766
Thiazide diuretics .056 .6828 −.075 .5850
Allopurinol .033 .8106 −.091 .5100
Eicosapentaeoic acid .172 .2085 .059 .6703
HMG-CoA RI −.034 .8035 −.183 .1811
Probucol .124 .3688 −.152 .2667
Alpha-tocopherol −.016 .9062 −.018 .8965
Predonisolone .146 .2888 −.120 .3839
aP ≤ 0.05.
the entire serum albumin, and HNA-1 constitutes most of
the remainder [15]. Forty percent of HSA is found within
blood vessels, and the remaining 60% outside blood ves-
sels in extracellular fluid [16]. Intravascular and extravas-
cular HSA moves beyond vessel walls and works as a
carrier of many substances. It has shown that approxi-
mately 10 g per hour of HSA travels in and out of blood
vessels [17]; this means that within an hour, approxi-
mately half of intravascular HSA is replaced with ex-
travascular HSA. These findings suggest that the redox
state of HSA may represent the global redox state of the
entire organism, in other words, that it directly reflects
the degree of oxidative stress.
Besides the redox state of HSA, many kinds of oxida-
tive stress markers have been widely used, including 8 hy-
droxy 2′ deoxyguanine oxidized low-density lipoprotein
and F2 isoprotanes. These markers are in vivo substances,
such as DNA and lipids, which have been denatured due
to oxidation. All these are useful and suitable for evalu-
ating the degree of influence oxidative stress on various
Table 4. The correlation between f(HNA-(1+2)), f(HNA-2), and
clinical data
f(HNA-total) f(HNA-2)
R P value R P value
Systolic blood pressure .265 .0510 .133 .3317
Diastolic blood pressure .133 .3322 .051 .7138
Body mass index .004 .9762 −.040 .7575
Total protein −.087 .5293 −.027 .8426
Albumin −.241 .0763 −.080 .5628
Alanine aminotransferase −.148 .2807 .027 .8429
Urea nitrogen .454a .0005 .508a <.0001
Creatinine .529a <.0001 .618a <.0001
Uric acid .466a .0003 .244 .0730
Sodium −.066 .6304 −.202 .1392
Chloride .009 .9492 .006 .9658
Potassium .037 .7880 .135 .3269
Calcium −.136 .3228 −.216 .1131
Inorganic phosphate .011 .9352 .157 .2533
Magnesium .328a .0145 .443a .0007
Total cholesterol −.173 .2068 −.218 .1103
HDL cholesterol −.125 .3646 −.215 .1141
Total iron −.213 .1181 −.240 .0776
C-reactive protein .118 .3913 .144 .2931
Hemoglobin −.439a .0008 −.284a .0355
Creatinine clearance −.525a <.0001 −.539a <.0001
Salt excretion −.103 4557 −.218 .1091
Estimated protein intake −.334a .0126 −.193 .1586
f(HNA-total), fractions of human non-mercaptalbumin-1 and 2; f(HNA-2),
fractions of human non-mercaptalbumin-2; R, regression coefficient.
aP ≤ 0.05.
in vivo substances, but the redox state of HSA might be
more appropriate when evaluating oxidative stress of an
entire organism.
There have been reports in the past on the proportion
of oxidized albumin being significantly increased among
hemodialysis [15, 18–20] and peritoneal dialysis [20] pa-
tients; but similar examinations among predialysis pa-
tients with renal failure have not been reported. To our
knowledge, our paper is the first to clarify that the pro-
portion of oxidized albumin is already increased before
dialysis, and that it exhibits a negative correlation with
remaining renal functions.
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Table 5. The result of multiple regression analysis
f(HNA-total) f(HNA-2)
(P < .0001) (P < .0001)
R P value R P value
Creatinine .395 .0036 .597 <.0001
Uric acid .271 .0415 — —
Age — — .240 .0203
Magnesium — — .293 .0054
Abbreviations are: f(HNA-total), fractions of human non-mercaptalbumin-1
and 2; f(HNA-2), fractions of human non-mercaptalbumin-2; R, standard
regression coefficient; SBP, systolic blood pressure.
To date, it is still unclear why a decrease of renal func-
tion promotes oxidative stress. Although there are many
reports on the relationship of in vivo antioxidant enzymes
and renal function, opinions seem to diverge when it
comes to analyze the relationship between renal function,
antioxidant enzyme activity of renal cortex, and that of
serum [4–7, 21, 22].
Meanwhile, accumulated uremic toxins (which include
reactive carbonyl compounds), per se, may be inducible
oxidative stress. It is reported that by performing dialysis
on patients with renal failure, decreased activity of serum
glucose-6-phosphate dehydrogenase, superoxide dismu-
tase, and calatase all began to show normal values [4], and
the proportion of oxidized albumin began to decrease [15,
18, 19]. Furthermore, Wratten et al incubated various ure-
mic substances (carboxymethyllysine, methyl glyoxal, p-
cresol, hippuric acid) together with bovine serum albumin
at 37◦C and observed a decrease of the sulfhydril group,
formation of dityrosine, and advanced oxidation protein
products [22]. These reports seem to indicate the strong
possibility that the primary culprit of oxidative stress in
chronic renal failure could possibly be the accumulation
of “oxidative” uremic toxins.
Our examination demonstrated that oxidative stress is
increased before dialysis among patients with chronic re-
nal failure. The following facts support the validity and
significance of antioxidant treatment for predialysis renal
failure patients in terms of prevention of cardiovascular
disease: (1) a large number of renal failure patients al-
ready present with cardiovascular disease at the time they
reach dialysis [1]; (2) incidences of cardiovascular disease
are higher in renal failure patients than among subjects
with normal renal function, even before dialysis [2]; and
(3) dialysis patients who received antioxidant treatment
exhibited some positive results [8, 9].
Furthermore, results obtained from examinations us-
ing animal models of renal failure also suggest the possi-
bility that antioxidant substance administration inhibits
histologic renal damage [23–25]. In other words, antioxi-
dant treatment may not only be useful for the prevention
of cardiovascular disease, but also for the amelioration of
renal damage progression.
Two types of approaches are conceivable in terms of
antioxidant treatment for predialysis renal failure: the ad-
ministration of antioxidant substances, and the removal
of “oxidative” uremic toxins. With regard to the former,
the clinical effects of vitamin E [8] and acetylcysteine
[9] have already been reported, and their administration
might be a valid course, although more studies need to be
performed in order to conform these results. Otherwise,
some animal experiments further suggest the usefulness
of buckwheat extract [23], green tea polyphenol [24], and
lazaroid [26]. With regard to the latter, these animal ex-
periments suggest the usefulness of the oral administra-
tion of activated charcoal [27] and the early initiation of
peritoneal dialysis [27]. Further examinations are, how-
ever, required to assess the usefulness and merits of these
therapies among predialysis patients with renal failure.
Besides creatinine, uric acid, magnesium, and age were
adopted as significant explanatory variables with multi-
ple (forward stepwise) regression analysis. Although this
result is interesting, the meaning of it is uncertain at the
present.
CONCLUSION
By measuring the redox state of HSA, we demon-
strated that oxidative stress correlates with the degree of
renal dysfunction and is promoted even before patients
with chronic renal failure reach dialysis. Therefore, in the
future, antioxidant strategies should be encouraged to
become part of the treatment of patients with predialysis
renal failure.
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